Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058

By David A M C van de Vijver, Ann-Kathrin Richter, Charles A B Boucher, Barbara Gunsenheimer-Bartmeyer, Christian Kollan  Brooke Nichols  Christoph D Spinner, J├╝rgen Wasem, Knud Schewe, Anja Neumann  |  | 

Our objective was to assess cost-effectiveness and costs of introducing PrEP in Germany.We calibrated a deterministic mathematical model to the human immunodeficiency virus (HIV)epidemic among MSM in Germany. PrEP was targeted to 30% of high-risk MSM. It was assumed that PrEP
reduces the risk of HIV infection by 85%. Costs were calculated from a healthcare payer perspective usinga 40-year time horizon starting in 2018. Introduction of PrEP in Germany can reduce the HIV epidemic among MSM in a cost-saving manner. PrEP is predicted to remain cost-saving even when generic versions of antiretroviral drug treatment become available.

Publication details

Euro Surveillance